Photocure ASA 

€6.3
0
+€0.24+3.96% Today

Statistics

Day High
6.32
Day Low
6.04
52W High
6.75
52W Low
4.02
Volume
0
Avg. Volume
47
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.03
-0.01
0.01
0.03
Expected EPS
0.0323570272611
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHS.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie competes in the bladder cancer space with treatments that could be seen as alternatives to Photocure's diagnostic solutions.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG offers a range of oncology treatments, including diagnostics and therapeutics that could compete with Photocure's bladder cancer detection and treatment products.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb has a portfolio of oncology products that could serve as alternatives to Photocure's offerings, particularly in the bladder cancer segment.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. provides a variety of cancer treatments, including immunotherapies that could compete with Photocure's bladder cancer solutions.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has a broad oncology portfolio, including treatments for bladder cancer that could compete with Photocure's products.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC has a strong presence in the oncology market, including treatments that could compete with Photocure's bladder cancer diagnostics and therapeutics.
Novartis
NVS
Mkt Cap297.35B
Novartis AG offers a wide range of cancer treatments, including therapies for bladder cancer that could be seen as competitive to Photocure's products.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops oncology treatments that could compete with Photocure's bladder cancer solutions.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline plc has a portfolio of oncology products, including treatments for bladder cancer that could compete with Photocure's offerings.
Sanofi
SNY
Mkt Cap113.88B
Sanofi offers oncology treatments, including those for bladder cancer, that could serve as alternatives to Photocure's diagnostic and therapeutic products.

About

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Show more...
CEO
Mr. Daniel Schneider
Employees
102
Country
Other
ISIN
NO0010000045

Listings

0 Comments

Share your thoughts

FAQ

What is Photocure ASA stock price today?
The current price of PHS.STU is €6.3 EUR — it has increased by +3.96% in the past 24 hours. Watch Photocure ASA stock price performance more closely on the chart.
What is Photocure ASA stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Photocure ASA stocks are traded under the ticker PHS.STU.
Is Photocure ASA stock price growing?
PHS.STU stock has risen by +22.09% compared to the previous week, the month change is a +6.96% rise, over the last year Photocure ASA has showed a +40.31% increase.
When is the next Photocure ASA earnings date?
Photocure ASA is going to release the next earnings report on May 07, 2026.
What were Photocure ASA earnings last quarter?
PHS.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.02 EUR resulting in a -3.45% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Photocure ASA have?
As of April 15, 2026, the company has 102 employees.
In which sector is Photocure ASA located?
Photocure ASA operates in the Energy sector.
When did Photocure ASA complete a stock split?
Photocure ASA has not had any recent stock splits.
Where is Photocure ASA headquartered?
Photocure ASA is headquartered in Oslo, Other.